-
Integration of genetic and clinical risk factors improves the risk classification of uveitis in patients with juvenile idiopathic arthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-19 Melissa Tordoff, Samantha L. Smith, Saskia Lawson-Tovey, , Andrew D. Dick, Michael W. Beresford, Athimalaipet V. Ramanan, Kimme L Hyrich, Andrew P Morris, Stephen Eyre, Lucy R Wedderburn, John Bowes
Juvenile idiopathic arthritis (JIA)-associated uveitis (JIAU) is a serious JIA comorbidity that can result in vision impairment. This study aimed to identify genetic risk factors, within the major histocompatibility complex , for JIAU and evaluate their contribution for improving risk classification when combined with clinical risk factors.
-
Risk factors of mortality in patients with rheumatoid arthritis-associated interstitial lung disease: a single-centre prospective cohort study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-19 Yeo-Jin Song, Hyoungyoung Kim, Soo-Kyung Cho, Hye Won Kim, Chaewhi Lim, Eunwoo Nam, Chan-Bum Choi, Tae-Hwan Kim, Jae-Bum Jun, Sang-Cheol Bae, Dae Hyun Yoo, Su Jin Hong, Seung-Jin Yoo, Youkyung Lee, Yoon-Kyoung Sung
To determine the risk factors for mortality in Korean patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) in comparison to patients with RA but without ILD (RA-nonILD). Data were extracted from a single-centre prospective cohort of RA patients with a chest computed tomography scan at an academic referral hospital in Korea. Patients with RA-ILD enroled between May 2017
-
Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-18 Panagiota Xanthouli, Paul Uesbeck, Hanns-Martin Lorenz, Norbert Blank, Christina A. Eichstaedt, Satenik Harutyunova, Benjamin Egenlauf, Jerry G. Coghlan, Christopher P. Denton, Ekkehard Grünig, Nicola Benjamin
In the EDITA trial, patients with systemic sclerosis (SSc) and mild pulmonary vascular disease (PVD) treated with ambrisentan had a significant decline of pulmonary vascular resistance (PVR) but not of mean pulmonary arterial pressure (mPAP) vs. placebo after six months. The EDITA-ON study aimed to assess long-term effects of open label therapy with ambrisentan vs. no pulmonary arterial hypertension
-
Stabilizing the integrity of intestinal barrier to control arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-18 George D. Kalliolias, Athanasios G. Papavassiliou
With great interest, we have read the recent article “Expression of HIF1α in intestinal epithelium restricts arthritis inflammation by inhibiting RIPK3-induced cell death machinery” published by Lyu et al. in Annals of the Rheumatic Diseases. The authors pose that the expression of hypoxia-inducible factor 1 alpha in intestinal epithelial cells represents a crucial check point for the development of
-
Performance of the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome in a Mexican cohort Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-19 Erik Cimé‐Aké, Gabriela Hernández‐Molina, Amaya Llorente‐Chávez, Eduardo Martín‐Nares
ObjectiveTo assess the performance of the 2023 ACR/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) in a Mexican cohort.MethodsWe enrolled patients with primary (PAPS) and secondary APS (SAPS), and a control group of non‐autoimmune thrombophilia. We evaluated the fulfillment of the 2023 AECC and the 2006 Revised Sapporo classification criteria (2006 RSCC), and their performance
-
Gut microbiome and osteoarthritis: insights from the naturally occurring canine model of OA Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-19 Christina Stevens, Samantha Norris, Liubov Arbeeva, Scott Carter, Masataka Enomoto, Amanda E. Nelson, B. Duncan X. Lascelles
ObjectivesThe purpose was to enhance the current knowledge of the relationship between the gut microbiome and osteoarthritis (OA) and associated pain using pet dogs as a clinically relevant translational model.MethodsFecal samples were collected from 93 owned pet dogs. Dogs were designated either clinically healthy or OA‐pain using validated methods. Metagenomic profiling was performed through shotgun
-
Distinct phenotype and prognosis of immune-mediated necrotizing myopathy based on clinical-serological-pathological classification Rheumatology (IF 4.7) Pub Date : 2024-07-19 Hongxia Yang, Lining Zhang, Xiaolan Tian, Wenli Li, Qingyan Liu, Qinglin Peng, Wei Jiang, Guochun Wang, Xin Lu
Objective The aim of the study was to investigate the characteristics and prognosis of patients with immune-mediated necrotizing myopathy (IMNM) based on clinical, serological and pathological classification. Methods A total of 138 patients with IMNM who met the 2018 European Neuromuscular Center criteria for IMNM including 62 anti-SRP, 32 anti-HMGCR-positive and 44 myositis specific antibody-negative
-
Development of a measuring app for systemic sclerosis-related digital ulceration (SALVE: Scleroderma App for Lesion VErification) Rheumatology (IF 4.7) Pub Date : 2024-07-18 Adrian K Davison, Ashma Krishan, Robert P New, Andrea Murray, Graham Dinsdale, Joanne Manning, Frances Hall, John D Pauling, Andy Vail, Kathryn Kearney, Helen Patrick, Michael Hughes, William Dixon, Mark Dickinson, Chris Taylor, Ariane L Herrick
Objectives To test the hypothesis that photographs (in addition to self-reported data) can be collected daily by patients with systemic sclerosis (SSc) using a smartphone app designed specifically for digital lesions, and could provide an objective outcome measure for use in clinical trials. Methods An app was developed to collect images and patient reported outcome measures (PROMS) including Pain
-
Subclinical Aortic Inflammation in Patients with Polymyalgia Rheumatica Rheumatology (IF 4.7) Pub Date : 2024-07-18 Mahmut S Kaymakci, Gerald J Berry, Hannah E Langenfeld, Andrew C Hanson, Cynthia S Crowson, Melanie C Bois, Hartzell V Schaff, Yuki Sato, Kevin-Phu C Le, Matthew J Koster, Cornelia M Weyand, Kenneth J Warrington
Objectives To examine the clinicopathologic features of patients with polymyalgia rheumatica (PMR) who had thoracic aorta repair surgery. Findings were compared with those of a cohort of patients with giant cell arteritis (GCA) requiring thoracic aorta repair. Methods All patients evaluated at Mayo Clinic in Rochester, MN, with Current Procedural Terminology (CPT) codes for thoracic aorta repair surgery
-
Trimethoprim sulfamethoxazole prophylaxis and serious infections in granulomatosis with polyangiitis treated with rituximab Rheumatology (IF 4.7) Pub Date : 2024-07-18 Arielle Mendel, Hassan Behlouli, Évelyne Vinet, Jeffrey R Curtis, Sasha Bernatsky
Objective To assess the association of trimethoprim sulfamethoxazole (TMP-SMX) prophylaxis with serious infections in rituximab-treated patients with granulomatosis with polyangiitis (GPA). Methods This retrospective cohort study included adults with GPA (2011–2020) within the United States Merative™ Marketscan® Research Databases with ≥6 months enrolment prior to first (index) rituximab treatment
-
JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-17 Jing Luo, Jing Zhang, Bomiao Ju, Yanhua Wang, Nan Hu, Qian Li, Qianyun Xu, Dan Pu, Zhiming Hao, Yongwei Huo, Xiaohong Lv, Lan He
To investigate the distribution and activation of B-cell subpopulations in rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKis) and to analyze their correlation with disease remission. Peripheral blood samples were collected from 23 adult healthy controls and 58 RA patients, 31 of whom were treated with JAKis and assessed during a 24-month follow-up. The number of peripheral
-
Skeletal muscle composition, power, and mitochondrial energetics in older men and women with knee osteoarthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-17 Giovanna Distefano, Stephanie Harrison, John Lynch, Thomas M. Link, Philip A. Kramer, Sofhia V. Ramos, Theresa Mau, Paul M. Coen, Lauren M. Sparks, Bret H. Goodpaster, Peggy M. Cawthon, Jane A. Cauley, Nancy E. Lane
ObjectiveTo investigate the overall and sex‐specific relationship between presence and severity of knee osteoarthritis (KOA) with muscle composition, power, and energetics in older adults.MethodsMales and females (n=655, 76.1±4.9yrs; 57% females) enrolled in the Study of Muscle, Mobility and Aging (SOMMA) completed standing knee radiographs and knee pain assessments. Participants were divided into
-
Do functionality, strength, vascularization, inflammatory and biopsychosocial status improve by biopsychosocial model-based exercise in SSc? Rheumatology (IF 4.7) Pub Date : 2024-07-17 Orkun Tüfekçi, Edibe Ünal, Batuhan Erhan Aktaş, Aziz Anıl Tan, İrem Hartuç Çevik, Erdem Karabulut, Aslı Pınar, Feza Korkusuz, Mehmet Ruhi Onur, Sedat Kiraz, Ali Akdoğan
Objectives This study aimed to investigation of the effects of the Cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY), a supervised biopsychosocial model-based exercise intervention, on functionality, muscle strength, vascularization, anti-inflammatory and biopsychosocial status in Systemic Sclerosis (SSc) patients. Methods Thirty-seven SSc patients were included. Twenty
-
Integrin signalling in joint development, homeostasis and osteoarthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-16 Michael Z. Miao, Janice S. Lee, Kenneth M. Yamada, Richard F. Loeser
-
A novel method to monitor rheumatoid arthritis prevalence using hospital and medication databases Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-16 Louise Koller-Smith, Ahmed Mehdi, Lyn March, Leigh Tooth, Gita D. Mishra, Ranjeny Thomas
Most estimates of rheumatoid arthritis (RA) prevalence, including all official figures in Australia and many other countries, are based on self-report. Self-report has been shown to overestimate RA, but the ‘gold standard’ of reviewing individual medical records is costly, time-consuming and impractical for large-scale research and population monitoring. This study provides an algorithm to estimate
-
Clinical relevance of positively determined myositis antibodies in rheumatology: a retrospective monocentric analysis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-16 Falk Schumacher, Maximilian Zimmermann, Malte Kanbach, Wigbert Schulze, Maximilian Wollsching-Strobel, Doreen Kroppen, Sarah Bettina Stanzel, Daniel Majorski, Wolfram Windisch, Johannes Strunk, Melanie Berger
The increased availability of myositis autoantibodies represents new possibilities and challenges in clinical practice (Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–64
-
HLA-B5 prevalence in patients with spondyloarthritis and impact on disease phenotype: a multicentric case-control study Rheumatology (IF 4.7) Pub Date : 2024-07-16 Nelly Ziade, Sarah Bou Jaoude, Rhéa Nacouzi, Kamel Mroue’, Georges Merheb, Samira Klayme, Pierre Ghorra
Objective The study aimed to estimate the prevalence of HLA-B51 and HLA-B52 in Lebanese patients with spondyloarthritis (SpA) compared to healthy controls (HC). We further aimed to evaluate the impact of HLA-B51 on phenotype and identify the distribution of the alleles in the HLA-B locus. Methods A case-control study enrolled consecutive SpA patients from three rheumatology clinics in Lebanon, including
-
TGFβ signaling pathway is altered by HLA-B27 expression, resulting in pathogenic consequences relevant for spondyloarthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-15 Marc Lauraine, Maxence de Taffin de Tilques, Dganit Melamed-Kadosh, Bilade Cherqaoui, Vincent Rincheval, Erwan Prevost, Aurore Rincheval-Arnold, Eneida Cela, Arie Admon, Isabelle Guénal, Luiza M. Araujo, Maxime Breban
Association of HLA-B27 with spondyloarthritis (SpA) has been known for 50 years, but still remains unexplained. We recently showed that HLA-B27 expressed in wing imaginal disc from HLA-B27/human-β2 microglobulin (hβ2m) transgenic Drosophila deregulated bone morphogenetic protein (BMP) pathway by interacting physically with type I BMP receptor (BMPR1) Saxophone (Sax), leading to crossveinless phenotype
-
Single cell RNA and T-cell receptor sequencing reveals substantive similarities between synovial fluid and synovial tissue T-cells in inflammatory arthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Lucy E. Durham, Frances C Humby, Nora Ng, Sarah Ryan, Rosamond Nuamah, Kathy Fung, Athul Menon Kallayil, Pawan Dhami, Bruce W. Kirkham, Leonie S. Taams
-
Long-term outcomes of childhood-onset systemic lupus erythematosus Rheumatology (IF 4.7) Pub Date : 2024-07-13 A Mirguet, F A Aeschlimann, I Lemelle, R Jaussaud, P Decker, T Moulinet, S Mohamed, P Quartier, M Hofer, O Boyer, A Belot, A Hummel, N Costedoat-Chalumeau, B Bader-Meunier
Objective Data on the long-term outcome of patients with childhood-onset Systemic Lupus Erythematosus (cSLE) are scarce. Aims of this study were to describe the long-term outcomes of cSLE and to identify factors associated with the development of damage and persistent disease activity. Methods We conducted a retrospective multicentre study using data from the PEDIALUP registry of the Juvenile Inflammatory
-
A double-blind, placebo-controlled, randomized multiple dose phase 1b trial of a CDK4/6 inhibitor, TCK-276, in patients with active rheumatoid arthritis Rheumatology (IF 4.7) Pub Date : 2024-07-13 Daisuke Tasaki, Kazuoki Tsuruda, Shosho Sun, Yoshinori Tsumura, Satoshi Asano, Yuki Suzuki, Shunsuke Tsujimoto, Daishiro Miura, Hiroaki Sato
Objective The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics, and efficacy (as an exploratory endpoint) of TCK-276, a novel CDK4/6 inhibitor, after multiple oral doses for 7 days in patients with active RA. Methods This multicentre, randomized, placebo-controlled, dose-ascending, double-blind, phase 1b, multiple-dose study included 32 patients with active RA in 4 cohorts
-
The impact of periodontitis and periodontal treatment on rheumatoid arthritis outcomes: an exploratory clinical trial Rheumatology (IF 4.7) Pub Date : 2024-07-13 Daniela S Silva, Charlotte De Vries, João Rovisco, Sara Serra, Marta Kaminska, Piotr Mydel, Karin Lundberg, José P Silva, Isabel P Baptista
Objective Studies suggest rheumatoid arthritis (RA) patients could benefit from periodontal treatment. However, published data are inconsistent, and there is a need for better-controlled research. Our study aims to address these limitations. Methods In this exploratory randomised delayed-start study, 22 RA patients with moderate/severe periodontitis were subjected to full-mouth debridement. Periodontal
-
Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicenter real-world study Rheumatology (IF 4.7) Pub Date : 2024-07-13 Charlotte Gabilan, Julie Belliere, Olivier Moranne, Pierre Pfirmann, Maxime Samson, Vincent Delattre, Benjamin Thoreau, Victor Gueutin, Annabel Boyer, Amélie Leurs, Quentin Astouati, Charles Ronsin, Thomas Quemeneur, David Ribes, Alexandre Karras, Stanislas Faguer
Objectives Avacopan, a selective C5aR1 inhibitor, recently emerged as a glucocorticoid (GCs) sparing agent in ANCA-associated vasculitis (AAV). We aim to evaluate the tolerance and efficacy of avacopan given outside randomized clinical trials or with severe kidney involvement. Methods In this multicentre retrospective study, we reviewed the clinical charts of patients with AAV and contraindication
-
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-11 Megan P. Leask, Tania O. Crișan, Aichang Ji, Hirotaka Matsuo, Anna Köttgen, Tony R. Merriman
-
Serum GM-CSF level is a predictor of treatment response to tocilizumab in rheumatoid arthritis patients: a prospective observational cohort study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-12 Jingbo Su, Wenlu Hu, Yanxia Ding, Panpan Zhang, Tianfang Li, Shengyun Liu, Lihua Xing
The aim of this prospective observational cohort study was to unveil the predictors of treatment response to tocilizumab (TCZ) therapy in rheumatoid arthritis (RA) patients, in terms of clinical characteristics and serum proinflammatory cytokines, especially to explore the predictive value of granulocyte macrophage-colony stimulating factor (GM-CSF). Active adult RA patients with inadequate response
-
The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection – a novel disease-modifying osteoarthritis drug Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-12 Khaled Elhady Mohamed, Anna Thorsø Larsen, Simone Melander, Frederik Andersen, Ellen Barendorff Kerrn, Morten Asser Karsdal, Kim Henriksen
Despite the extensive research to provide a disease-modifying osteoarthritis drug (DMOAD), there is still no approved DMOAD. Dual amylin and calcitonin receptor agonists (DACRA) can provide metabolic benefits along with antinociceptive and potential structural preserving effects. In these studies, we tested a DACRA named KBP-336 on a metabolic model of OA in meniscectomised (MNX) rats. We evaluated
-
A genome-wide association study suggests new susceptibility loci for primary antiphospholipid syndrome Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Desiré Casares-Marfil, Manuel Martínez-Bueno, Maria Orietta Borghi, Guillermo Pons-Estel, , Guillermo Reales, Yu Zuo, Gerard Espinosa, Timothy Radstake, Lucas L. van den Hoogen, Chris Wallace, Joel Guthridge, Judith A James, Ricard Cervera, Pier Luigi Meroni, Javier Martin, Jason S. Knight, Marta E. Alarcón-Riquelme, Amr H. Sawalha
-
Itaconate targets fibroblast-like synoviocytes in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-10 Sarah Onuora
Treatment with the endogenous metabolite itaconate induced phenotypic and metabolic changes in fibroblast-like synoviocytes and reduced the severity of arthritis in an animal model.
-
Update on the pathophysiology and treatment of primary Sjögren syndrome Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-09 Chiara Baldini, Giovanni Fulvio, Gaetano La Rocca, Francesco Ferro
-
Critical Review and Recommendations for Enhancing the Analysis of Climate Change Impacts on Rheumatic Conditions Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-10 Xiaozhen Zhao, James Cheng‐Chung Wei, Caifeng Li
-
Air Pollution, Genetic Susceptibility, and Risk of Incident Systemic Lupus Erythematosus: A Prospective Cohort Study Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-10 Meiqi Xing, Yudiyang Ma, Feipeng Cui, Dankang Li, Jianing Wang, Linxi Tang, Lei Zheng, Jian Yang, Yaohua Tian
ObjectiveThere are few existing studies that investigate the risk of systemic lupus erythematosus (SLE) associated with long‐term exposure to air pollutants. This study aimed to explore associations between long‐term exposure to air pollutants and incident SLE and further evaluate interactions and joint effects of genetic risk and air pollutants.MethodsA total of 459,815 participants were included
-
Correction: Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-09 Javier Narvaez, Elena Canadillas, Ivan Castellvi, Juan Jose Alegre, Vanesa Vicens‑Zygmunt, Guadalupe Bermudo, Paola Vidal-Montal, Maria Molina Molina, Joan Miquel Nolla
Correction: Arthritis Res Ther 26, 122 (2024) https://doi.org/10.1186/s13075-024-03353-2 Following publication of the original article [1], the authors identified an error in the author name of Vanesa Vicens‑Zygmunt. The incorrect author name is: Vanesa Vincens‑Zygmunt. The correct author name is: Vanesa Vicens‑Zygmunt. The author group has been updated above and the original article [1] has been corrected
-
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-09 Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster, Jonathan H. Chung, Sonye K. Danoff, Michael D. George, Dinesh Khanna, Gordon Guyatt, Reza D. Mirza, Rohit Aggarwal, Aberdeen Allen, Shervin Assassi, Lenore Buckley, Hassan A. Chami, Douglas S. Corwin, Paul F. Dellaripa, Robyn T. Domsic, Tracy J. Doyle, Catherine Marie Falardeau, Tracy M. Frech, Fiona K. Gibbons, Monique Hinchcliff, Cheilonda
ObjectiveWe provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs).MethodsWe developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment
-
Pathogenic antibodies target stromal antigens in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-08 Jessica McHugh
New findings identify HSP60 and other synovial stromal-derived autoantigens as targets for pathogenic autoantibodies, exacerbating arthritis and serving as potential biomarkers.
-
Integrin-mediated ILC2 adhesion protects against lupus nephritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-08 Jessica McHugh
Type 2 innate lymphoid cells protect against kidney inflammation in lupus nephritis, and enhancing their adhesion via integrin α4β7 upregulation, particularly through IL-33 treatment, could be a promising therapeutic approach.
-
The Relationship between the complement system and subclinical carotid atherosclerosis in patients with rheumatoid arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-08 Marta Hernández-Díaz, Dara Rodríguez-González, Elena Heras-Recuero, Fuensanta Gómez-Bernal, Juan Carlos Quevedo-Abeledo, Agustín F. González-Rivero, Elena González-López, J. Gonzalo Ocejo-Vinyals, Alejandro Jimenez-Sosa, Miguel Ángel González-Gay, Iván Ferraz-Amaro
Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Subclinical carotid atherosclerosis is independently associated with rates of incident CV events among patients with RA. The complement system has been related to both the etiopathogenesis of RA and CV disease. In this study, we aimed to evaluate the association between a comprehensive assessment
-
Weighing the Cardiovascular Risks of Low‐Dose Glucocorticoids in Rheumatoid Arthritis from Real‐World Data Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Tate M. Johnson
-
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster, Jonathan H. Chung, Sonye K. Danoff, Michael D. George, Dinesh Khanna, Gordon Guyatt, Reza D. Mirza, Rohit Aggarwal, Aberdeen Allen, Shervin Assassi, Lenore Buckley, Hassan A. Chami, Douglas S. Corwin, Paul F. Dellaripa, Robyn T. Domsic, Tracy J. Doyle, Catherine Marie Falardeau, Tracy M. Frech, Fiona K. Gibbons, Monique Hinchcliff, Cheilonda
ObjectiveWe provide evidence‐based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease.MethodsWe developed clinically relevant population
-
Mapping and analysis of protein and gene profiles identify the important role of TGF‐β in synovial invasion in pigmented villonodular synovitis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Tao Li, Yan Xiong, Jian Li, Xin Tang, Yutong Zhong, Zhigang Tang, Qiuping Zhang, Yubin Luo
BackgroundPigmented villonodular synovitis (PVNS) is a rare benign proliferative disease affecting the soft tissue lining the synovial joints and tendons. Its etiology is poorly understood, largely limiting the availability of current therapeutic options. Here, we mapped the synovial gene and protein profiles of patients with PVNS, revealed a link between synovial inflammation and invasion, and elucidated
-
Genetically proxied IL-13 inhibition is associated with risk of psoriatic disease: Mendelian randomization study Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Sizheng Steven Zhao, Kimme Hyrich, Zenas Yiu, Anne Barton, John Bowes
-
Impact of conventional and biological disease-modifying anti-rheumatic drugs on arterial lesions in Takayasu arteritis Rheumatology (IF 4.7) Pub Date : 2024-07-06 Diego Bletry, Louis Meyblum, Kristell Desseaux, Mathieu Vautier, Laurent Chiche, Alexandre Le Joncour, Alban Redheuil, Charles Roux, Patrice Cacoub, Julien Gaudric, Lucie Biard, David Saadoun
Background The definition of Takayasu arteritis (TAK) remission and disease activity is still unclear. Vascular imaging is an essential tool for following-up patients. Herein, we aimed to compare the evolution of vascular lesions (i.e. vessel wall thickening and stenosis) under conventional cDMARDs relatively to biological DMARDs (bDMARDs) in TAK patients followed with the same CT angiography modalities
-
Refining treat-to-target strategies in cryopyrin-associated periodic syndromes: the role of inflammatory markers Rheumatology (IF 4.7) Pub Date : 2024-07-06 Özlem Satirer, Tatjana Welzel, Beate Zapf, Susanne M Benseler, Jasmin B Kuemmerle-Deschner
Objectives Cryopyrin-associated periodic syndromes (CAPS) encompasses a spectrum of IL-1 driven systemic diseases with dramatic individual and societal burden. The study aimed to identify parameters and instruments to refine real-life treat-to-target (T2T) strategies and control CAPS disease activity. Methods A single-centre, longitudinal study of consecutive children and adults diagnosed with CAPS
-
How muscle influences bone health Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-05 Maria Papatriantafyllou
FNIP1- and TFEB-dependent secretion of IGF2 by dystrophic muscles contributes to muscle–bone crosstalk.
-
-
ERG regulates lymphatic vessel specification genes and its deficiency impairs wound healing‐associated lymphangiogenesis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-05 Takashi Yamashita, Ulas Kaplan, Adri Chakraborty, Grace Marden, Sami Gritli, Daniel Roh, Andreea Bujor, Marcin Trojanowski, Giovanni Ligresti, Jeffrey L Browning, Maria Trojanowska
-
Association of autoantibody concentrations and trajectories with lupus nephritis histological features and treatment response Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-04 Andrea Fava, Catriona A. Wagner, Carla J. Guthridge, Joseph Kheir, Susan Macwana, Wade DeJager, Tim Gross, Peter Izmirly, H. Michael Belmont, Betty Diamond, Anne Davidson, Paul J. Utz, Michael H Weisman, Laurence S. Magder, , Joel M. Guthridge, Michelle Petri, Jill Buyon, Judith A. James
Autoantibodies are a hallmark of lupus nephritis (LN), but their association with LN classes and treatment response are not adequately known. In this study, we quantified circulating autoantibodies in the Accelerating Medicines Partnership (AMP) LN longitudinal cohort to identify serological biomarkers of LN histological classification and treatment response, and how these biomarkers change over time
-
Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF inhibitor Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-04 Zhaohui Yang, Panfeng Tao, Xu Han, Anna Kozlova, Tingyan He, Egor Volchkov, Zoya Nesterenko, Dmitryi Pershin, Elena Raykina, Timur Fatkhudinov, Anastasia Korobeynikova, Ivona Aksentijevich, Jun Yang, Anna Shcherbina, Qing Zhou, Xiaomin Yu
Autoinflammation and PLCγ2-associated antibody deficiency and immune dysregulation (APLAID) syndrome is an autoinflammatory disease caused by gain-of-function variants in PLCG2. This study investigates the pathogenic mechanism of a novel variant of PLCG2 in a patient with APLAID syndrome.
-
Determinants of Achieving Serum Urate Goal with Treat‐to‐Target Urate‐Lowering Therapy in Gout Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-04 Daniel Small
-
ANOTHER NOTCH IN THE BELT OF RHEUMATOID ARTHRITIS Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-04 Stephanie R. Zack, Osama Alzoubi, Neha Satoeya, Kunwar P. Singh, Sania Deen, Wes Nijim, Myles J. Lewis, Costantino Pitzalis, Nadera Sweiss, Lionel B. Ivashkiv, Shiva Shahrara
-
Investigation of ferroptosis-associated molecular subtypes and immunological characteristics in lupus nephritis based on artificial neural network learning Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-03 Li Zhang, Qing Yan, Miao Lin, Juanjuan He, Jie Tian, Zhihan Chen, Fuyuan Hong
Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) with poor treatment outcomes. The role and underlying mechanisms of ferroptosis in LN remain largely unknown. We aimed to explore ferroptosis-related molecular subtypes and assess their prognostic value in LN patients. Molecular subtypes were classified on the basis of differentially expressed ferroptosis-related genes
-
Could tocilizumab be used in familial Mediterranean Fever? A systematic review Rheumatology (IF 4.7) Pub Date : 2024-07-01 P Mertz, V Hentgen, S Georgin-Lavialle
Introduction Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease characterized by recurrent fever and serosal inflammation. Although colchicine is the primary treatment, around 10% of FMF patients do not respond to it, necessitating alternative therapies. Biologic treatments, such as interleukin-1β (IL-1β), TNF-α, and interleukin-6 (IL-6) inhibitors, have been considered
-
Coronary-Artery Calcification progression in lupus patients. J. Rheumatol. (IF 3.6) Pub Date : 2024-07-01 Mario Cesar Ocampo-Torres, Gabriela Hernández-Molina, Sergio Criales-Vera, Jorge Sánchez-Guerrero, Pilar Lara-Reyes, Juanita Romero-Díaz
To evaluate the progression of coronary-artery calcification (CAC) and risk factors associated in a SLE cohort.
-
Systemic sclerosis sine scleroderma: a time of re-appraisal. J. Rheumatol. (IF 3.6) Pub Date : 2024-07-01 Anastasios Makris, Alexandros Panagiotopoulos, Oliver Distler, Petros P Sfikakis
Systemic sclerosis sine scleroderma (ssSSc), formally described in 1962, is a subset of SSc which, unlike limited (lcSSc) and diffuse cutaneous (dcSSc) forms, lacks skin fibrosis. According to the 2013 ACR/EULAR criteria, SSc can be diagnosed in the absence of skin thickening, even if this is expected to develop later in disease course. Driven by a fatal case of ssSSc with cardiac involvement, we analysed
-
Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial Spondyloarthritis. J. Rheumatol. (IF 3.6) Pub Date : 2024-07-01 Sherry Rohekar, Jordi Pardo Pardo, Reza Mirza, Sibel Zehra Aydin, Louis Bessette, Nicolas Richard, Dianne Mosher, Tristan Boyd, Jon Chan, Lihi Eder, Laura Passalent, Elie Karam, Bindu Nair, Glen S Hazlewood, Shirley Tse, Dax Rumsey, Michel Zummer, Nigil Haroon, Robert Inman, Dafna Gladman
To provide a set of living treatment recommendations that will provide contemporary guidance on the management of patients with axial spondyloarthritis (axSpA) in Canada.
-
Examining the Case for Palliative Care in Patients with Systemic Sclerosis. J. Rheumatol. (IF 3.6) Pub Date : 2024-07-01 Julie McDonald, Laura Ross, Carolyn Wicks, Jennifer Philip
Systemic sclerosis is a complex, multi-organ disease which causes substantial and progressive symptoms and impairs quality of life. International guidelines recommend early, integrated palliative care for patients with advanced cardiopulmonary disease such as heart failure, and interstitial lung disease, as this care can improve patient, caregiver and health care outcomes. In this article, we examine
-
Validation of Different Dementia Code-based Definitions in a Population-based Study of Rheumatoid Arthritis. J. Rheumatol. (IF 3.6) Pub Date : 2024-07-01 Maria Vassilaki, Roslin Jose George, Rakesh Kumar, Edward Lovering, Sara J Achenbach, Suzette J Bielinski, Jennifer St Sauver, John M Davis, Cynthia S Crowson, Elena Myasoedova
Rheumatoid arthritis (RA) has been associated with an elevated dementia risk. The study aimed to examine how different diagnostic dementia definitions perform in those with RA compared to individuals without RA.
-
Chronic Nonbacterial Osteomyelitis in Children: Exploring the Interplay of Sleep, Pain, Quality of Life, and Disease Activity. J. Rheumatol. (IF 3.6) Pub Date : 2024-07-01 Reem Habib-Simaan, Merav Heshin Bekenstein, Irit Tirosh, Shiri Speilman, Rotem Semo-Oz, Ruby Haviv, Gil Amarilyo, Yonatan Butbul Aviel
Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease that most commonly affects children and adolescents.1 Pain is a common problem in pediatric rheumatic diseases, with adolescents reporting reduced physical functioning, school absenteeism, anxiety, and depression.2.
-
"Gallia est omnis divisa in partes tres": Social Media Platforms as a New Educational Channel for Pediatric Rheumatology. J. Rheumatol. (IF 3.6) Pub Date : 2024-07-01 Saverio La Bella, Luciana Breda, Angelo Ravelli
Technological progress is changing the way we connect and interact, leading to growing modifications of communication strategies and social dynamics. Younger generations have in part changed their main information sources from traditional print journals to more interactive online resources.
-
Prevalence and Risk Factors of Post-Acute Sequela of COVID-19 in Adults with Systemic Autoimmune Rheumatic Diseases. J. Rheumatol. (IF 3.6) Pub Date : 2024-07-01 Mayan S Teles, Janetta Brundage, Teresa Po-Yu Chiang, Jennifer L Alejo, Nicolas Henriquez, Rachel Wallwork, Lisa Christopher Stine, Allan Massie, Dorry L Segev, Caoilfhionn M Connolly, Julie J Paik, William A Werbel
Incidence and manifestations of post-acute sequelae of COVID-19 (PASC) are poorly defined among immunosuppressed populations. We reported, phenotyped, and assessed risk factors for PASC in adults with systemic autoimmune diseases.
-
Scleroderma Renal Crisis: Clues From the Physical Exam. J. Rheumatol. (IF 3.6) Pub Date : 2024-07-01 Aakash V Patel, Alex M Tinianow, Phillip V Petrasko, John H Stone
Scleroderma renal crisis (SRC) is a rare, life-threatening complication of systemic sclerosis (SSc) and can sometimes be the first manifestation of the disease.1 A 56-year-old female presented with acute encephalopathy requiring intubation and a systolic blood pressure of 230 mmHg; no information was available about her medical history.